OUR MISSION

OUR MISSION

Based on the platform of self-assembling peptides, a technology developed at the Massachusetts Institute of Technology (MIT) in the U.S., our group is expanding its business globally in the areas of surgery, regenerative medicine, and drug delivery systems (DDS).
We contribute to the advancement of medicine through biomaterials.

Link to global site
SCROLL

NEWS

  • ALL
  • IR
  • NEWS
MORE

We are developing a number of applications using self-assembling peptides in three main medical fields.

  • Surgical Treatment

    Surgical
    Treatment

    With a focus on Purestat, which has the strength not only in hemostasis but also in overall strength, we are developing postoperative bleeding materials, mucous membrane lifting-up solutions, vascular embolization materials and so on.

  • Regenerative Medicine

    Regenerative
    Medicine

    We are developing products for radiation proctitis (RP), inflammatory bowel disease (IBD), wound healing in the field of cosmetic surgery, and bone and heart muscle regeneration.

  • DDS

    DDS

    Based on the DDS technology to make the required drug act at the required site for the required length of time, we are promoting the delivery of nucleic acid drugs for cancer and malignant pleural mesothelioma.

Investors

ABOUT US

This section provides information about 3-D Matrix.

MORE
ABOUT US